Drug Trial Radar · NCT01946204
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,207
Actual
Start
Oct 14, 2013
Primary completion
May 19, 2017
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Aragon Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Conditions
- Prostatic Neoplasms
Interventions
ApalutamideDrug
240 mg tablets administered by mouth on a continuous once daily dosing regimen
PlaceboDrug
Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 43 Months
Locations
379 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Anchorage, Alaska
Site not named
Chandler, Arizona
Site not named
Tucson, Arizona
Site not named
Duarte, California
Site not named
Fullerton, California
Site not named
Laguna Woods, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Roseville, California
Site not named
Sacramento, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Sherman Oaks, California
Site not named
Stanford, California
Site not named
Tarzana, California
Site not named
Torrance, California
Site not named
Denver, Colorado
Site not named
Englewood, Colorado
Site not named
Glenwood Springs, Colorado
Site not named
Grand Junction, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Aventura, Florida
Site not named
Boca Raton, Florida
Site not named
Bradenton, Florida
Site not named
Daytona Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
New Port Richey, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
St. Petersburg, Florida
Site not named
Wellington, Florida
Site not named
Meridian, Idaho
Site not named
Chicago, Illinois
Site not named
Decatur, Illinois
Showing 40 of 379 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.